‘A game-changer’: How Spartan retooled its patented rapid DNA test to tackle COVID-19
Ottawa biotech firm predicts revenues will top $200 million this year – and only rise from there.
‘A game-changer’: How Spartan retooled its patented rapid DNA test to tackle COVID-19
Ottawa biotech firm predicts revenues will top $200 million this year – and only rise from there.
Get up-to-date news about the companies, people and issues that impact businesses in Ottawa and beyond.
Sponsored